Northwire Canada EditionFriday, July 10, 2026
Northwire
GGX 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.43 +12.6% TUNG 1.74 +3.0% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.58 +2.3% SGZ 0.040 −11.1% GRSL 0.305 −4.7% DEX 0.380 −1.3% GGX 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.43 +12.6% TUNG 1.74 +3.0% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.58 +2.3% SGZ 0.040 −11.1% GRSL 0.305 −4.7% DEX 0.380 −1.3%
M&A / Property Routine +

Realbotix Provides Update on Nasdaq Listing

Nasdaq Listing Update Confirms Path to Liquidity

Executive Summary
  • Realbotix Corp. provided an update on its reverse takeover transaction with Onconetix, Inc. (NASDAQ: ONCO).
  • The transaction aims to list Realbotix LLC (commercial robotics/AI subsidiary) on the Nasdaq Capital Market by October 2026.
  • Parent Company will retain a 75–90% ownership stake in the resulting Nasdaq-listed entity upon closing.
  • No new shares will be issued by the Parent Company, and no share consolidation is required for existing shareholders.
  • Realbotix will appoint four out of five directors to the ONCO board at closing.
  • The strategic rationale includes unlocking value in commercial robotics, separating it from direct-to-consumer business, and accessing non-dilutive financing via Nasdaq.
Material Impact
  • Status Update: This news is a follow-up to the February 12, 2026 announcement of the reverse takeover agreement; therefore, it does not contain genuinely new strategic information but confirms progress on an existing deal.
  • Valuation Impact: Listing on Nasdaq Capital Market typically improves liquidity and access to institutional investors compared to TSX Venture, which is a positive structural change for valuation multiples over time.
  • Dilution Concerns: The confirmation that no new shares will be issued by the Parent Company mitigates immediate dilution risk for existing shareholders, preserving their 75–90% interest in the listed entity.
  • Operational Context: This update must be weighed against Q1 2026 financial results released March 9, which showed a 57% year-over-year revenue decline ($353k vs $815k), indicating operational headwinds despite the capital market progress.
  • Risk Mitigation: The deal structure allows Realbotix to maintain control while accessing US capital markets, but execution risk remains regarding regulatory approvals (TSX Venture and ONCO shareholders).
XBOT · Price
Company Overview
  • Company: Realbotix Corp., a TSX Venture listed entity focused on AI-powered humanoid robotics.
  • Flagship Project: Realbotix LLC, a subsidiary specializing in autonomous humanoid robots for healthcare, education, hospitality, and entertainment sectors.
  • Technology: Proprietary AI vision system "Vinci" enabling eye contact maintenance, user recognition, and emotional signal capture; embedded on-device AI models running without cloud reliance.
  • Commercialization: Recent deployments include Ericsson (workforce training/visitor engagement) and The FUTR Corporation (AI agents in physical world).
  • Facilities: Relocating robotics operations to a new Las Vegas corridor facility by late June 2026 to support scaled production.
Read the original news release →

More from Realbotix Corp.